title: FDA OK's Iclusig's return to market.
abstract: With new safety measures in place, the U.S. Food and Drug Administration will allow Ariad Pharmaceuticals to resume marketing Iclusig, sales of which were suspended in October 2013.
mesh_terms: D017277:Drug Approval; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib